Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 65 | SFEBES2019 | Next issue

Society for Endocrinology BES 2019

Brighton, United Kingdom
11 Nov 2019 - 13 Nov 2019

Card image cap
Come and exchange knowledge, share experiences and strengthen collaborations across our global community of endocrinologists!

POSTER PRESENTATIONS

Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer

ea0065p130 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Nuclear receptor profiling predicts chemical disruptors as risk factors for developing breast cancer

Leif Freya , Pfander Pauline , Baker Syed Murtuza , Donaldson Ian , McGinnis Kathryn , Leslie Fiona , Thorne James , Cook Graham , Twelves Christopher , Speirs Valerie , Matthews Laura

Triple negative breast cancer (TNBC) represents 10–20% of all breast cancers diagnosed, affects young people and is highly aggressive. These tumours lack expression of the receptors that bind estrogen and progesterone and stratify patients for hormonal therapy. The only current therapeutic option for TNBC is chemotherapy which has limited efficacy, and therefore novel therapies are desperately needed. The receptors for estrogen and progesterone belong to the nuclear recep...

ea0065p131 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Inflammatory cytokines dysregulate oestrogen metabolism in colorectal cancer

Banibakhsh Afnan , Hardy Rowan , Foster Paul

Colorectal cancer (CRC) is the third most common cancer and is one of the highest incidences and mortality tumours worldwide. Our group has previously shown that CRC favours oestradiol synthesis by increasing steroid sulfatase (STS) activity and altering 17β-hydroxysteroid dehydrogenases (HSD17Bs) expression. However, what regulates STS activity and HSD17Bs expression and activity in CRC remains unknown. In breast and prostate cancer inflammatory mediators, such as TNF&#9...

ea0065p132 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Risk stratification of variants of unknown significance (VUS) in monogenic endocrine tumour genes using population-level genetic data and computational analysis

Vennard Hannah , Maroteau Cyrielle , Berg Jonathan , Goudie David , Palmer Colin , Newey Paul

Background: Identifying individuals harbouring germline mutations in hereditary cancer genes provides opportunities for tumour surveillance programs, disease-specific treatment and cascade testing in family members but is reliant on accurate variant interpretation, which may be confounded by imprecise methods for ascribing pathogenicity. Where insufficient evidence supports a definitive classification, ‘variant of uncertain significance’ (VUS) status is applied, whic...

ea0065p133 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Tumour detection and outcomes of surveillance screening in SDHB and SDHD mutation carriers

White Gemma , Masucci Michael , Anandappa Samantha , Joshi Mamta , McGowan Barbara , Obholzer Rupert , Jacques Audrey , Christodoulou Dimitra , Izatt Louise , Velusamy Anand , Carroll Paul

Background: Pathogenic variants in genes encoding Succinate Dehydrogenase subunits B and D (SDHB/SDHD) predispose to Phaeochromocytoma and Paraganglioma (PPGL). Cascade genetic screening identifies relatives at risk and allows surveillance screening to enable early detection of PPGLs.Methods: Retrospective analysis of genetic databases and hospital records between January 2000 and December 2018 identified relatives carrying SDHB and <em...

ea0065p134 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

PLK1 inhibitors as potential new treatment for adrenocortical carcinoma

Smith Gabrielle , Liang Raimunde , Chortis Vasileios , Lippert Juliane , Hantel Constanze , Altieri Barbara , Fassnacht Martin , Foster Paul , Ronchi Cristina

Background: Adrenocortical carcinoma (ACC) is a rare aggressive cancer with limited treatment options for advanced stages. By targeted RNA expression screening, we identified polo-like kinase 1 (PLK1) as one of most overexpressed genes, thus representing a potential drug target for ACC. PLK1 inhibitors are under evaluation in clinical trials for other solid cancers and seem to be more effective in TP53 mutated tumours. The aim of the study was to evaluate PLK1 protein levels i...

ea0065p135 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

The impact of gastrointestinal symptoms on quality of life in people with MEN2B

Goncharova Mariia , Grey Joanna , Druce Maralyn

Introduction: Besides medullary thyroid carcinoma and other endocrinopathies, people with MEN 2B have intestinal ganglioneuromatosis. A recent MEN2B cohort study reported high rates of gastrointestinal (GI) symptoms: we hypothesized these might have a major impact on patients’ daily lives.Methods: An online survey was conducted among patients from Association for Multiple Endocrine Neoplasia Disorders (AMEND). This incorporated relevant elements fro...

ea0065p136 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Profiling of tissue inflammatory cytokine expression in a pancreatic neuroendocrine tumour mouse model identifies upregulation of the chemokine C-C motif ligand 2 (CCL2)

Shariq Omair , Lines Kate , Stevenson Mark , Thakker Rajesh

Pancreatic neuroendocrine tumours (PNETs) may occur as part of the multiple endocrine neoplasia type 1 (MEN1) syndrome, or as a non-familial isolated endocrinopathy. Current medical treatments for PNETs are largely ineffective in preventing tumour progression, so there is a need for better therapies, which will develop from an improved understanding of the mechanisms driving PNET tumorigenesis. Cytokine-driven inflammation has been implicated in the development and progression...

ea0065p137 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Long term outcomes following parathyroidectomy in patients with multiple endocrine neoplasia type 1: A retrospective cohort study

Healy Ultan , English Katie , Bacon Hannah Elizabeth , Grossman Ashley B , Shine Brian , Thakker Rajesh V , May Christine JH , Pal Aparna , Mihai Radu , Jafar-Mohammadi Bahram

Primary hyperparathyroidism (PHP), usually due to multigland hyperplasia, occurs in >90% of patients with multiple endocrine neoplasia type 1 (MEN1). The literature is divided on the optimal surgical management for such patients. We report a retrospective cohort study on the long-term outcomes associated with limited, subtotal, or total parathyroidectomy as initial surgery for PHP in MEN1. The primary endpoint was recurrent PHP defined as an adjusted serum calcium >2.6 mmol/l ...

ea0065p138 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Targeting oestrogen synthesis and action as a novel therapy for colorectal cancer

Sidhu Daljit , Haime Hope , Pidd Aidan , Taylor Angela , Cox Liam , Foster Paul

Colorectal cancers (CRC) represent 9.4% of all cancers, with about 42 000 new UK cases per year. Current treatment involves surgical resection followed by radio- and chemo-therapy. 5-Fluorouracil is the standard post-operative chemotherapy although tolerance is poor due to dose-limiting toxicities and drug-resistance. New treatment strategies are therefore sorely needed. One emerging chemotherapeutic option is to target oestrogen metabolism. Our novel work rev...

ea0065p139 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Clinical spectrum of endocrine toxicities of Immune checkpoint therapy: single centre experience

Joshi Mamta , Duffy Leo , Velusamy Anand , Papa Sophie , Carroll Paul

Introduction: Checkpoint inhibitor (CPI) related endocrine toxicities are increasingly commonly with the use of these new cancer agents. With one of the largest cancer departments in UK, we studied the clinical management and outcome of patients who developed different endocrine toxicities over the last five years, with the use of CTLA-4, PD-1 and PDL-1 agents.Methods: All patients treated with CPI between 1 Jan 2014 to 31 Jan 2019 were included for the ...

ea0065p140 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

A cyclin dependent kinase inhibitor 1B missense mutation (Pro69Leu) is associated with familial hypomagnesaemia, but not multiple endocrine neoplasia type 4 (MEN4)

Stevenson Mark , Olinger Eric , Debaix Huguette , Vogt Bruno , Devuyst Olivier , Thakker Rajesh

Mutations in cyclin dependent kinase inhibitor 1B (CDKN1B) are associated with multiple endocrine neoplasia type 4 (MEN4), in which patients typically develop parathyroid and anterior pituitary tumours, and occasionally tumours of the pancreas, adrenals, kidneys and reproductive organs. Here, we report a family with a missense mutation of CDKN1B (p.Pro69Leu) that did not have MEN4-associated tumours, but instead had hypomagnesaemia. The proband, presented wit...

ea0065p141 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Predicting hypophysitis in patients treated with immune checkpoint inhibitors: can prolactin be used as a marker of incipient disease?

Noronha Sean , Pueyo Maria , Payne Miranda , Turner Helen

Background: Immune checkpoint inhibitors (ICIs), approved in the UK for the treatment of increasingly numerous malignancies, are commonly associated with endocrine sequelae, some of which may be life threatening. Society for Endocrinology guidelines detail management protocols for acute endocrinopathies, however widely accepted standards for their routine detection are lacking. Hypophysitis, clinically and radiologically silent in many, is seen in up to 15% of patients on ICIs...

ea0065p142 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Living with and beyond childhood cancer – endocrine impact up to 40 years on

Surandran Sanggeeta , Idama Ella , Windsor Rachael , Davies Melanie , Grandage Victoria , Simpson Helen

Objective: To review impact of childhood cancer treatment on endocrine, gonadal and thyroid function.Methods: Retrospective review of electronic records of 79 females, 90 males over 6 months of clinic visits from a Late Effects of childhood cancer clinic. Age at diagnosis: 8.5 years (range 5 months–9 years); time from treatment 23.5 years (range 10–40). Diagnoses: ALL, AML, Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma, sarcomas, Wilms, ...

ea0065p143 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Ipilimumab-induced hypophysitis: a longitudinal analysis in a cohort of patients with metastatic melanoma

Seejore Khyatisha , Osborn Djoah , Lynch Julie M , Marples Maria , Murray Robert D

Introduction: Ipilimumab is a human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 (CTLA-4) that has been shown to significantly improve survival in patients with metastatic melanoma. Immune-related adverse events (irAEs) occur in some patients with increased T-cell activation, of which ipilimumab-related hypophysitis (IH) is an important treatment complication. The aim of this study is to determine the incidence of IH and characterise clinical presentat...

ea0065p144 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

The yield and cost of radiological screening in von Hippel–Lindau disease

McMillan Timothy , Sahdev Anju , Evanson Jane , McAndrew Lorraine , Martin Lee , Paraskevopoulos Dimitrios , Bull Jonathan , Parvanta Laila , Gevers Evelien , Drake William , O'Toole Samuel

Introduction: Patients with the familial cancer syndrome von Hippel–Lindau disease (VHL) are enrolled in radiological screening programmes which aim to identify tumour development at an early stage. This facilitates timely intervention to lesions when the risk of metastatic spread is low and when they are conducive to less-invasive and parenchymal-sparing interventions, thereby minimising treatment-related morbidity. A number of international screening protocols exist, al...

ea0065p145 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

DI patients vote for a name change to pituitary insipidus to improve safety – a survey

Prentice Malcolm

Aims: To discover the views of patients with Diabetes Insipidus (DI) on difficulties they encounter with managing DI in different circumstances; the possible causes of these difficulties and how these might be improved for their safety.Background: Between 2009 and 2015 there were 471 serious adverse inpatient incidents and 2 deaths involving DDAVP administration1. The analysis of one death resulted in a suggestion that the name of the conditio...

ea0065p146 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Frequency of pathogenic germline variants in hereditary endocrine tumour genes in patients with discordant cancer phenotypes

Vennard Hannah , Maniam Pavithran , Berg Jonathan , Goudie David , Newey Paul

Background: Advances in next-generation sequencing facilitate the simultaneous evaluation of large numbers of cancer predisposition genes (CPGs) in patients with cancer irrespective of family history or tumour phenotype. Several studies have reported the frequent occurrence of germline mutations in CPGs in patients with discordant cancer types raising the possibility of novel gene-cancer associations. The current study aimed to evaluate the significance of germline mutations i...

ea0065p147 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Lobectomy for thyroid cancer and thyroglobulin as a tumor marker for long term follow up: current controversies and clarification

Jeeyavudeen Mohammad Sadiq , Graveling Alex , Shakeel Muhammad , Smart Louise , Tasleem Sadia , Aspinall Sebastian , Abraham Prakash

Background: The accuracy of thyroglobulin (Tg) as a tumour marker following lobectomy for differentiated thyroid cancer (DTC) remains controversial. A Tg (<10 µg/l) looked promising in identifying those without clinically apparent recurrence after median 51 months of follow-up. Longer term follow up allows assessment of the diagnostic utility of thyroglobulin in predicting relapse.Methods: Ninety-nine patients who underwent lobectomy for DTC wer...

ea0065p148 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

An audit on a teenage and young adult (TYA) neuro-oncology and late effects clinic

Chow Anthea , Zammitt Nicola N , Wright Rohana J

Introduction: Due to improved cancer survival rates, a rising number of CNS cancer survivors face late effects of therapy, such as hormone deficiencies. During adolesecence and young adulthood, specialised transition services are needed to cater for young peoples complex health needs and general needs, such as achieving independence. This study therefore audited a Teenage & Young Adult (TYA) neuro-oncology late effects clinic to identify areas of good practice and areas fo...

ea0065p149 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Prolonged supervised fast for insulinoma – an experience in a District General Hospital Trust

Khan Haris , Nawaz Maimoona , Arul-Devah Vilashini , Ashraf Fahad Hassan , Pichaipillai Lakshminarayanan

Introduction: Insulinoma a neuroendocrine tumour is diagnosed by inappropriately raised Insulin concentrations during a spontaneous or induced episode of hypoglycaemia. A provocative 72-h supervised fast is done to evaluate suspected inappropriate insulin secretion. Our aim is to see if it is feasible for a shorter duration of fast is enough to confirm Insulinoma.Method and results: In our Trust we analysed retrospectively in the last 10 years, ...

ea0065p150 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Breast cancer in MEN1: coincidence or association?

Cheah Seong Keat , Bisambar Chad , Pitfield Deborah , Giger Olivier , Hoopen Rogier ten , Martin Jose Ezequiel , Clark Graeme , Park Soo-Mi , Parkinson Craig , Challis Bejamin , Casey Ruth

A 38 year old female was identified as carrying a heterozygous pathogenic MEN1 variant (c.13404delG) through predictive testing, following a diagnosis of familial hyperparathyroidism. Routine screening for hyperparathyroidism and pituitary disease was negative. However, a CT thorax-abdomen-pelvis revealed a 41 mm pancreatic tail mass. Biopsy via endoscopic ultrasound confirmed a well-differentiated (grade 1) pancreatic neuroendocrine tumour (pNET) with MIB1<1%. Bi...

ea0065p151 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

A post implementation audit of a local Chromogranin A service – a step towards individualised patient care

Frank Amy , Smith Karen

Background: Neuroendocrine tumours are rare tumours that arise from neuroendocrine cell types which are widespread throughout the body. These tumours can develop in many different organs and secrete a variety of hormones making biochemical monitoring of treatment/progression challenging. Previously patients at Beatson West of Scotland Cancer Centre were monitored using either a full gut hormone profile (GHP) or chromogranin A and B (CGs) measured at Charing Cross Hospital. A n...

ea0065p152 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

The expression pattern of miR-16, 21, 145, and 375 in plasma of breast cancer patients at different clinical stages

Samuel Aderonke , James Ayorinde , Habeebu Muhammad , Polycarp Juliet , Yalaju Lesley , Obaka Samuel , Adebayo Oluwaseyi

Current challenges in the management of breast cancer includes a continuous search for sensitive and specific minimally invasive biomarkers that can be exploited to detect early neoplastic changes, thus facilitating the detection of breast cancer at an early stage, as well as for monitoring the progress of patients with breast cancer and their response to treatments. This study investigated the expression pattern of miR-16, 21, 145, and 375 in plasma of breast cancer patients ...

ea0065p153 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Ipilimumab-induced hypophysitis with normal pituitary function: a series of 3 cases

Nogueira Edson , Morganstein Daniel

Introduction: Hypophysitis has been recognised as a frequent endocrine related side effect of immunotherapy with the CLTA-4 inhibitor Ipilimumab, with a prevalence of upto 17.4%. The most common symptoms of hypophysitis are headache and signs/symptoms of hypopituitarism. Whilst some patients have an enlarged pituitary on MRI, this is frequently normal. ACTH and TSH deficiencies are most common, but all anterior and posterior pituitary hormonal axis may be affected. Hypopituita...

ea0065p154 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Checkpoint inhibitors and immune related diabetes mellitus: a case series

Hanafy Ahmed , Seejore Khyatisha , Kyriakakis Nikolaos , Al-Qaissi Ahmed , Kassim Saifuddin , Marples Maria , Murray Robert D

Introduction: Checkpoint inhibitors (CPi) are finding a place in the treatment algorithm of an increasing number of cancers. Immune-related (ir) endocrinopathies are frequent side-effects. Diabetes mellitus (irDM) is infrequent, but often presents acutely and can be potentially life-threatening There are ˜60–70 cases characterising irDM in the literature. We describe 4 cases of irDM to add to the understanding of this condition. All four patients were undergoing trea...

ea0065p155 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Carney’s triad due to SDHA gene mutation

Arabi Noon , Healy Ultan , Pal Aparna , Jafar-Mohammadi Bahram , May Christine

Carney’s triad; a diagnosis based on the presence of three associated neoplasms; epithelioid leiomyosarcoma, pulmonary chondroma, and extra-adrenal paraganglioma remains a rare diagnosis. Here we report a 52-year-old female investigated for chronic cough. Initial chest X-ray demonstrated calcified masses, and CT thorax confirmed a left pulmonary lesion measuring 41 mm in diameter with 3 adjacent smaller nodules up to 20 mm. A chondroid pattern o...

ea0065p156 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Insulinoma causing remission of diabetes mellitus type 2

Oroko Maroria , Cairns Ross , Azharuddin Mohammed

We present the case of a 77-year-old woman with a medical history of diabetes mellitus type 2 and hypothyroidism who was admitted to hospital after having had episodes of recurrent symptomatic hypoglycaemia. The patient had diabetes mellitus type 2 for 26 years and this had gone into remission over the previous 2 years: she had been having recurrent hypoglycaemia necessitating reduction in insulin doses and then subsequent discontinuation of therapy altogether. There was a his...

ea0065p157 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Audit of biochemical screening for multiple endocrine neoplasia type 1 in patients diagnosed with pancreatic neuroendocrine tumours

Marguerie David , Al-Mrayat Ma'en

Background: Pancreatic Neuroendocrine Tumours (pNETs) can be associated with cancer susceptibility syndromes such as Multiple Endocrine Neoplasia type 1 (MEN1). MEN1 increases a person’s chance of developing pNETs, which are the main cause of mortality in this cohort. A diagnosis of pNETs, therefore, provides the opportunity for detection of associated MEN1 and subsequent identification of asymptomatic relatives who would then undergo relevant clinical, biochemical and ra...

ea0065p158 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Palliative electrochemotherapy treatment in a patient with advanced thyroid papillary carcinoma with cutaneous metastases

Cavaco Daniela , Carvalhal Sara , Vicente Helena , Leite Valeriano

Advanced papillary thyroid carcinoma (PTC) with cutaneous metastases may cause pain, ulceration and bleeding. Electrochemotherapy (ECT) is a minimally invasive oncologic treatment of tumours located in the skin and subcutaneous tissue. The electric pulses potentiates the toxicity of a cytostatic agent entering the tumour cell. It is highly effective especially to relieve pain and improve quality of life. The adverse events are local and transient. A case of progressive metasta...

ea0065p159 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Recurrent hyperparathyroidism in a patient with multiple endocrine neoplasia type 1 (MEN1) after total parathyroidectomy with autotransplantation unmasked by depression and vague abdominal pain

Alameri Majid , Fiad Tarek

Total parathyroidectomy with autotransplantation of parathyroid tissue is one of the treatment modalities for primary hyperparathyroidism in Multiple endocrine neoplasia type 1 (MEN1). Many of these patients are young and recurrence may take decades to emerge. We present a case of a 45-year-old woman who was diagnosed with MEN syndrome type 1 at the age of 12. Over the years, she underwent multiple surgical interventions including pituitary macroprolactinoma resection resultin...

ea0065p160 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Irradiation and endocrinopathies: multiple complications in a single patient

Zaman Shamaila , Khalid Neelam , Mohsin Zaineb , Siddiqui Mohsin , Todd Jeannie F

Endocrinopathies are common complications following cancer therapy and may occur decades later. We present a case of 37 year old lady with a background of chronic myeloid leukaemia (CML) which was treated with sibling allogenic stem cell transplant and total body irradiation in 2002. She was noted to have elevated calcium levels with raised PTH 10 years later. In view of young age, she underwent genetic screening for MEN1 through buccal swab as her lymphocytes were not suitabl...

ea0065p161 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

A rare case of Small cell lung carcinoma with dual ADH and ACTH secretion

Malik Tooba , Grigoras Cristina Eliza

This is a case of a patient diagnosed with small cell lung carcinoma after presenting with severe hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) who was readmitted 7 months later with refractory hypokalemia and hyperglycaemia due to ectopic adrenocorticotrophic hormone secretion (EAS). A 65 year-old man presented in November 2018 with symptoms of nausea, vomiting, headaches and blurred vision. On examination he was clinically euvolemic. La...

ea0065p162 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Transient adrenal insufficiency in a patient with an insulinoma

Gill Georgina , Ra Amelle , Thu-Ta Pinky , Connolly Maya , Evans Paul , Srinivas-Shankar Upendram

A 45-year-old man with obesity (BMI 36 kg/m2) was admitted with a 12-hour history of headache and confusion and managed for viral meningitis. Treatment was discontinued after CSF viral PCR was negative. At presentation, he was hypoglycaemic with a capillary glucose of 1.6 mmol/l. Past medical history was not significant and there were no similar episodes previously. He denied taking insulin, other medications, illicit drugs or alcohol. Initial investigations reveale...

ea0065p163 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Impact of diabetes education in patients with newly diagnosed diabetes

Soong Elaine , Tauni Rahat Ali

Diabetes education plays a vital role especially in newly diagnosed patients to prevent long-term complications and hospital admissions. We present a 68-year old female who was admitted with nausea, vomiting and poor oral intake. She was discharged two weeks ago after having complete pancreatectomy, splenectomy and left adrenalectomy for pancreatic cancer and a left adrenal mass. She did not have past medical history of diabetes and was commenced on basal bolus insulin after s...

ea0065p164 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Case report on Immunotherapy mediated hypocortisolemia

Varghese Jeanny , Humphriss David

63 year old gentleman, admitted in Nov 2018. Feeling generally unwell, decreased appetite, lethargy and poor mobility. Known lung cancer (diagnosed January 2018) On Immunotherapy last received in October 2018CT scan (September 2018) after 4 cycles of Pembrolizumab–excellent response to treatment. Routine blood tests were normal apart from a raised CRP at 551 and white cell count. A random cortisol level was done and found to be low at 135. Blood, urine, sputum and stool c...

ea0065p165 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

A case of pituitary metastatic deposit from breast cancer

Vijay Arun , Rangan Srinivasa , Singh Prashant , Moulik Probal

Introduction: Metastatic lesion in the pituitary is a rare condition with most of them being asymptomatic. Breast cancer is the most frequent primary location and the overall prognosis is poor. We describe the case of a lady with this condition, who presented to our unit with bitemporal hemianopia.Case: A 65 year old lady with history of breast cancer (surgical excision with chemoradiotherapy 4 years ago, HER2 negative, currently in remission) presented ...